Back to News
Market Impact: 0.34
GUTS Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in Fractyl Health, Inc. Securities Class Action
Source: prnewswire.com
Healthcare & BiotechAnalyst EstimatesAnalyst Insights
Morgan Stanley cut Fractyl Health's (GUTS) price target 75%, to $2.00 from $8.00, and downgraded the stock to Equal-weight. The reassessment follows concerns about an "outlier site" in Revita DMR clinical data, highlighted by Canaccord Genuity, creating a material credibility and valuation overhang for the biotech.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.58
Ticker Sentiment
GUTS-0.82
More News
- If You Invest $1,000 a Year in Morgan Stanley (MS) Stock, How Much Dividend Income Could It Generate Over 20 Years?
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)